Biocryst Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
BioCryst Pharmaceuticals, Inc. has issued its proxy statement for the Annual Meeting of Stockholders scheduled for June 11, 2026, detailing proposals for director elections, auditor ratification, executive compensation, and stock incentive plan amendments.
NASDAQ
BioCryst Pharmaceuticals announces its 2025 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation vote, and stock incentive plan approval.
NASDAQ
BioCryst Pharmaceuticals is asking stockholders to approve an amended stock incentive plan to increase the number of shares available for issuance at the annual meeting on June 12, 2025.
NASDAQ
BioCryst Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
BioCryst Pharmaceuticals is asking stockholders to approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000.